First treatment to address underlying pathophysiology of XLH backed by NICE

21 June 2024

UK health technology assessor the National Institute for Health and Care Excellence (NICE) has approved Crysvita (burosumab) from Japanese drugmaker Kyowa Kirin (TYO: 4151).

The company noted that Crystiva is the first treatment that addresses the underlying pathophysiology of X-linked hypophosphatemia (XLH) for use in adults – a long-awaited decision for patients who have seen the treatment used in Scotland since March 2023.

After a negative interim decision and lengthy consultation period, Crysvita is now recommended on the National Health Service (NHS) for the treatment of adults living with XLH in England, Wales and Northern Ireland.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK